The factor structure of the Mystical Experience Questionnaire (MEQ): Reply to Barrett & Griffiths (2016) Read More > January 25, 2017
The factor structure of the Mystical Experience Questionnaire (MEQ): Reply to Barrett & Griffiths (2016) Read More > January 25, 2017
Reply to: Ketamine and Psychosis History: Antidepressant Efficacy and Psychotomimetic Effects Postinfusion Read More > January 23, 2017
The fibrinolytic system: A new target for treatment of depression with psychedelics Read More > January 23, 2017
Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects Read More > January 20, 2017
Determination of Tryptamines and β-Carbolines in Ayahuasca Beverage Consumed During Brazilian Religious Ceremonies Read More > January 19, 2017
Pharmacology and Toxicology of N-Benzylphenethylamine (“NBOMe”) Hallucinogens Read More > January 18, 2017
Harmine, a Novel DNA Methyltransferase 1 Inhibitor in the Leukemia Cell Line Read More > January 17, 2017
Tackling Harm Reduction, Human Rights and Drug Uses on Recreational Environments: Tensions, Potentialities and Learnings from the Kosmicare Project (Portugal) Read More > January 16, 2017
